Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Tesofensine is a small-molecule triple monoamine reuptake inhibitor (serotonin, norepinephrine, dopamine) — NOT a peptide. Originally developed by NeuroSearch for Parkinson's and Alzheimer's disease (which it failed to benefit) and repositioned for obesity by Saniona. Not FDA-approved in the US.
Lowest Price
$60.00
Highest Price
$120.00
Average Price
$93.00
Potential Savings
67%
across 3 options
1 of 3 vendors are lab-verified for Tesofensine
We cross-check each vendor's Certificate of Analysis against the issuing lab's own verification portal — so “cheapest” isn't the only signal.
Best price trend
Lowest $/mg for Tesofensine · last 45 days
$3.00/mg
flat
Trust grade first, cheapest within grade
capsule · 0.5mginstantpeptides.com· price updated yesterday
Lot TES05002026-01· tested 2026-03-11
$240.00/mg
18% more per mg
capsule · 0.5mgpeptidesupplyco.com· price updated 3d ago
Lot TFE50004072026· tested 2026-04-11
$198.00/mg
vial · 0.1mghydroresearchpeptides.com· price updated today
$600.00/mg
67% more per mg
vial · 0.5mgamc-essentials.com· price updated today
$199.99−50%
$99.99$199.98/mg
1% more per mg
Prices are estimates and may vary. For research use only. We may earn a commission on purchases through affiliate links. Not medical advice.
Check formulation: Lyophilized powder requires reconstitution before use. Pre-mixed solutions are more convenient but may have a shorter shelf life and higher prices.
Compare per-mg cost: Different strengths and quantities make direct price comparison difficult. Calculate the per-milligram cost to find the true best value.
Verify COAs: Look for vendors that publish per-batch Certificates of Analysis from named, accredited labs. Every vendor on this page is verified for endotoxin testing — not just HPLC purity.
Pivotal Phase 2 (Astrup et al., Lancet 2008, n=203, 24 weeks, Denmark) showed placebo-subtracted weight loss of 4.5%, 9.2%, and 10.6% at 0.25, 0.5, and 1.0 mg/day — roughly twice orlistat at 0.5 mg. (The Lancet issued an expression of concern about that trial in 2013.) Saniona's Mexico partner Medix ran a Phase 3 registration study that met its primary endpoint; Medix filed with COFEPRIS in May 2023 with supplemental data submitted in 2024. As of April 2026 a final Mexican approval decision is still pending — the commonly repeated '2022 Mexico approval' claim is inaccurate. Tesomet (tesofensine + metoprolol, intended to blunt cardiovascular signal) is in development for hypothalamic obesity and Prader-Willi syndrome.
This platform provides informational tools only, not medical advice.
Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients — Astrup et al., Lancet
2008
Tesofensine pipeline page (mechanism, development status, Medix/Mexico partnership)
2026
Randomized controlled trial of Tesomet for weight loss in hypothalamic obesity (Huynh et al.)
Prices verified as of June 2026. Actual prices may vary. For research use only.
2022
Disclosed Labs